PubMed Health⌕ Search

PubMed · 15046503

First isolated active titanium peroxo complex: characterization and theoretical study.

Abstract

The protonated titanium peroxo complex [Bu(4)N](4)[HPTi(O(2))W(11)O(39)] (1) has been first prepared via interaction of the micro-oxo dimeric heteropolytungstate [Bu(4)N](8)[(PTiW(11)O(39))(2)O] (3) with an excess of 30% aqueous H(2)O(2) in MeCN. Peroxo complex 1 has been characterized by using elemental analysis, UV-vis, IR, resonance Raman (RR), (31)P and (183)W NMR spectroscopy, cyclic voltammetry, and potentiometric titration. The electronic and vibrational spectra of 1 are very similar to those of the well-known unprotonated titanium peroxo complex [Bu(4)N](5)[PTi(O(2))W(11)O(39)] (2), while (31)P and (183)W NMR spectra differ significantly. A compilation of the physicochemical techniques supports a monomeric Keggin type structure of 1 bearing one peroxo ligand attached to Ti(IV) in a eta(2)-coordination mode. The protonation of the titanium peroxo complex results in an increase of the redox potential of the peroxo group, E(1/2) = 1.25 and 0.88 V relative to Ag/AgCl reference electrode for 1 and 2, respectively. In contrast to 2, 1 readily reacts with 2,3,6-trimethylphenol (TMP) at 40 degrees C in MeCN to give 2,2',3,3',5,5'-hexamethyl-4,4'-biphenol (BP) and 2,3,5-trimethyl-p-benzoquinone (TMBQ). The proportion between BP and TMBQ in the reaction products depends on the TMP/1 ratio. When a 2-fold excess of TMP is used, the main reaction product is BP (90%), while using a 2-fold excess of 1 leads to TMBQ (95%). On the basis of the product study, a homolytic oxidation mechanism that implicates the formation of phenoxyl radicals is suggested. The RR deuterium labeling experiments show that the activating proton is most likely localized at a Ti-O-W bridging oxygen rather than at the peroxo group. Theoretical calculations carried out at the DFT level on the protonated and unprotonated titanium peroxo derivatives also propose that the most stable complex is formed preferentially after protonation of the Ti-O-W site; however, both Ti-OH-W and TiOO-H protonated anions could coexist in solution.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Oxana A Kholdeeva, Tatiana A Trubitsina, Raisa I Maksimovskaya, Anatolii V Golovin, Wade A Neiwert, Boris A Kolesov, Xavier López, Josep M Poblet. 2004-04-05. First isolated active titanium peroxo complex: characterization and theoretical study.. https://doi.org/10.1021/ic0354466

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗